Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCAR-T (KN3601) in Refractory Idiopathic Membranous Nephropathy
NCT07423572Phase 1Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Feb 2026
- Primary completion
- Feb 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KN3601 in idiopathic membranous nephropathy (IMN), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Incidence of Dose-Limiting Toxicity at 24 months and Overall Response Rate at 24 months. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
KN3601
03
Conditions
idiopathic membranous nephropathy (IMN)
Beyond the preview
Go deeper on NCT07423572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07423572.